An early spinal muscular atrophy (SMA) diagnosis with the help of a newborn screening program, and treatment with disease-modifying…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
An 8-month-old girl with a clinical and genetic diagnosis of spinal muscular atrophy (SMA) type 1 saw her…
A young girl whose muscle weakness and respiratory distress in infancy were treated only as such was diagnosed as a…
Researchers in China report having developed a way to quickly and more easily screen for people who carry SMN1 gene…
Among women of reproductive age in a southern region of China, one in every 59 tested in a screening program…
The case of a 4.5-year-old girl with spinal muscular atrophy (SMA) type 2 who had acute pain…
Voyager Therapeutics is collaborating with Novartis to discover and develop next-generation gene therapies for conditions like…
Researchers in the U.S. report using a gene-editing method to alter the SMN2 gene sequence, leading to normal levels of…
Revvity has launched its EONIS Q system for faster and simplified newborn molecular screening of spinal muscular…
NIDO-361, Nido Biosciences’ experimental oral treatment for spinal and bulbar muscular atrophy (SBMA), was seen to be…